Veregen® Receives Marketing Authorization in Israel, Denmark and Slovakia
Martinsried/Munich, August 1, 2012. Medigene AG (MDG, Frankfurt, Prime Standard) announced today that Veregen® for the treatment of genital warts has obtained marketing authorization in Israel, Denmark and Slovakia. Market launch of Veregen® in Denmark, Norway and Sweden by Medigene’s partner Azanta is expected early 2013 and market launch in Israel, by Medigene’s partner Teva, is expected during 2013.
Veregen® is already being marketed successfully in the USA (by Fougera), Germany and Austria (by Abbott), and Spain (by Bial). Marketing authorizations in additional countries are granted or expected within the next few months. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America and is planning to continue this global licensing strategy.
Veregen®: Veregen® (previously Polyphenon E® ointment), a topical treatment for external genital warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Medigene acquired the rights to the active ingredient in Veregen® from Epitome Pharmaceuticals, Inc. in 1999 and was solely responsible for the drug’s successful preclinical and clinical development, as well as the approval process. Sinecatechins 15% ointment (Veregen®) is recommended as a possible option for treating genital warts in the US Department of Health and Human Services Center for Disease Control and Prevention’s Sexually Transmitted Diseases Treatment Guidelines 2010.
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
– End –
Julia Hofmann & Kerstin Langlotz
Tel.: +49 – 89 – 20 00 33 – 33 01
Fax: +49 – 89 – 20 00 33 – 29 20
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.